About Obsidio
Obsidio is a company based in Solana Beach (United States) founded in 2018 by Ali Khademhosseini, Rahmi Oklu, and Ehsan Jabbarzadeh was acquired by Boston Scientific in August 2022.. Obsidio has raised $3 million across 4 funding rounds from investors including Boston Scientific, Good Growth Capital and National Heart, Lung, and Blood Institute. Obsidio operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Solana Beach, United States
- Founders Ali Khademhosseini, Rahmi Oklu, Ehsan Jabbarzadeh
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$3 M (USD)
in 4 rounds
-
Latest Funding Round
$2.1 M (USD), Grant
Jul 16, 2021
-
Investors
Boston Scientific
& 4 more
-
Employee Count
Employee Count
-
Acquired by
Boston Scientific
(Aug 15, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Obsidio
Obsidio has successfully raised a total of $3M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $2.1 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Grant — $2.1M
- First Round First Round
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Grant - Obsidio | Valuation |
investors |
|
| Aug, 2020 | Amount | Seed - Obsidio | Valuation | IAG Capital Partners | |
| Aug, 2020 | Amount | Grant - Obsidio | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Obsidio
Obsidio has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Boston Scientific, Good Growth Capital and National Heart, Lung, and Blood Institute. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are provided by IAG Capital Partners.
|
Founded Year | Domain | Location | |
|
Early-stage investments are made in life sciences and technologies.
|
Founded Year | Domain | Location | |
|
Venture capital fund backed by the US Government
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Obsidio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Obsidio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Obsidio Comparisons
Competitors of Obsidio
Obsidio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
Dental implants and regenerative dentistry products are developed.
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Obsidio
Frequently Asked Questions about Obsidio
When was Obsidio founded?
Obsidio was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Where is Obsidio located?
Obsidio is headquartered in Solana Beach, United States. It is registered at Solana Beach, California, United States.
Who is the current CEO of Obsidio?
Ehsan Jabbarzadeh is the current CEO of Obsidio. They have also founded this company.
Is Obsidio a funded company?
Obsidio is a funded company, having raised a total of $3M across 4 funding rounds to date. The company's 1st funding round was a Seed of $3M, raised on Aug 21, 2019.
What does Obsidio do?
Obsidio was founded in 2018 in Solana Beach, United States, within the medical technology sector focused on biomaterials. A shear-thinning biomaterial technology is being advanced for minimally invasive delivery of a polymer via catheter to stop blood flow. The material is designed to thin under pressure for injection and solidify upon pressure release, enabling applications such as hemorrhage control, tumor vessel occlusion, arteriovenous malformation prevention, and aneurysm treatment.
Who are the top competitors of Obsidio?
Obsidio's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Who are Obsidio's investors?
Obsidio has 5 investors. Key investors include Boston Scientific, Good Growth Capital, National Heart, Lung, and Blood Institute, IAG Capital Partners, and America’s Seed Fund.